ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CEACAM5 Antibody-drug Conjugate BMS-986490

Its studies are mostly in Colorectal Neoplasms, led by Bristol-Myers Squibb.

Furthest: phase 2, since Dec 9, 20241 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb11 open or runningphase 2since Dec 9, 2024Dec 9, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2024First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT06730750 · 360 enrolled · United States, Australia, Canada

TargetBeta

CEACAM5 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA) ”NCIt, by rule

Other programs on CEACAM5

ProgramCompanyFurthest phaseStudies
precemtabart tocentecanruleMerck KGaA, Darmstadt, Germanyphase 34
Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5Sino Biopharmaceuticalphase 22
Anti-CEACAM5 Antibody-drug Conjugate IBI3020ruleInnovent Biologicsphase 11
tusamitamab sonditecanPfizerphase 11
RO7821657ruleHoffmann-La Rochephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06730750Colorectal Neoplasms · United States, Australia, Canada2Active, not recruitingSep 5, 2026360

How it is read

Names in the registry

  • “BMS-986490”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.